Results 221 to 230 of about 49,720 (263)

Acute Myeloid Leukemia

Hematology, 2002
AbstractIn this chapter, Drs. Keating and Willman review recent advances in our understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions, including the advanced myelodysplastic syndromes (MDS), while Drs. Goldstone, Avivi, Giles, and Kantarjian focus on therapeutic data with an emphasis on current patient care and ...
Francis J, Giles, Armand, Keating, Anthony H, Goldstone, Irit, Avivi, Cheryl L, Willman, Hagop M, Kantarjian   +5 more
openaire   +2 more sources

Metabolomics in acute myeloid leukemia

Molecular Genetics and Metabolism, 2020
Acute myeloid leukemia (AML) is a complex, heterogenous hematological malignancy caused by mutations in myeloid differentiation and proliferation. Response to therapy and long-term outcomes vary widely based on chromosomal and molecular aberrations. Many platforms have been used to characterize and stratify AML.
Anna V, Wojcicki, Maya M, Kasowski, Kathleen M, Sakamoto, Norman, Lacayo   +3 more
openaire   +2 more sources

SEPHguarding acute myeloid leukemia

Cell Stem Cell, 2022
Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.
Malini, Gupta, Britta, Will
openaire   +2 more sources

Immunotherapy for Acute Myeloid Leukemia

Seminars in Hematology, 2015
Despite longstanding efforts in basic research and clinical studies, the prognosis for patients with acute myeloid leukemia (AML) remains poor. About half of the patients are not medically fit for intensive induction therapy to induce a complete remission and are treated with palliative treatment concepts.
Lichtenegger, F.S., Krupka, C., Köhnke, T., Subklewe, M.   +3 more
openaire   +3 more sources

Immunotherapy of Acute Myeloid Leukemia

Current Pharmaceutical Biotechnology, 2001
Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as ...
A E, Frankel, M R, Baer, D E, Hogge, R K, Stuart   +3 more
openaire   +2 more sources

Acute myeloid leukemia in adults

Current Treatment Options in Oncology, 2000
The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction.
L D, Cripe, S, Hinton
openaire   +2 more sources

Transplantation in Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2014
Acute myeloid leukemia (AML) is associated with poor outcome mainly because of relapse. The best antileukemic treatment is allogeneic stem cell transplantation. However, the associated significant nonrelapse mortality limits both the application and outcome of the procedure.
Tsila, Zuckerman, Jacob M, Rowe
openaire   +2 more sources

Angiogenesis in acute myeloid leukemia

Blood, 2000
We have read with interest the report of Padro et al[1][1] showing an increased angiogenesis in acute myeloid leukemia. Recently, other studies published in Blood also have shown that angiogenesis in acute myeloid leukemias is higher than in controls[2][2] and that it has an independent ...
DI RAIMONDO, FRANCESCO, G. A. PALUMBO, M. P. AZZARO, R. GIUSTOLISI   +3 more
openaire   +3 more sources

Pharmacogenomics in Acute Myeloid Leukemia

Pharmacogenomics, 2009
Acute myeloid leukemia (AML) in adults is a heterogeneous malignant pathology with a globally unfavorable prognosis. The classification of AML allows identification of subgroups with favorable prognosis. However, besides these specific subgroups, most patients will have an intermediate or unfavorable prognosis often resulting in induction failure ...
Christophe, Roumier, Meyling H, Cheok
openaire   +2 more sources

Immunophenotyping of Acute Myeloid Leukemia

2019
Immunophenotyping by multiparameter flow cytometry is a rapid and efficient technique to simultaneously assess and correlate multiple individual cell properties like size and internal complexity along with antigen expression in a population of cells. This method is utilized for rapid characterization of the blasts and classification of acute myeloid ...
Pallavi Kanwar, Galera, Chunjie, Jiang, Raul, Braylan   +2 more
openaire   +2 more sources